Alnylam Pharmaceuticals
ALNY
#638
Rank
โ‚ฌ26.68 B
Marketcap
206,18ย โ‚ฌ
Share price
1.76%
Change (1 day)
51.38%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -โ‚ฌ0.23 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are โ‚ฌ2.24 Billion. , an increase over its 2023 earnings that were of -โ‚ฌ0.28 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 -โ‚ฌ0.21 Billion-24.59%
2023 -โ‚ฌ0.28 Billion-67.84%
2022 -โ‚ฌ0.86 Billion36.93%
2021 -โ‚ฌ0.63 Billion-8.04%
2020 -โ‚ฌ0.68 Billion-15.66%
2019 -โ‚ฌ0.81 Billion12.23%
2018 -โ‚ฌ0.72 Billion62.91%
2017 -โ‚ฌ0.44 Billion17.78%
2016 -โ‚ฌ0.38 Billion43.44%
2015 -โ‚ฌ0.27 Billion60.69%
2014 -โ‚ฌ0.17 Billion98.2%
2013 -โ‚ฌ81.7 Million
2011 -โ‚ฌ48.19 Million27.48%
2010 -โ‚ฌ37.8 Million-10.92%
2009 -โ‚ฌ42.44 Million95.77%
2008 -โ‚ฌ21.68 Million
2006 -โ‚ฌ34.73 Million-9.13%
2005 -โ‚ฌ38.22 Million34.74%
2004 -โ‚ฌ28.37 Million36.79%
2003 -โ‚ฌ20.74 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-โ‚ฌ0.53 Billion 154.87%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ4.20 B-2,129.54%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ0.22 B-210.72%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚ฌ9.11 Million-95.60%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚ฌ40.61 Million-80.38%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ11.98 B-5,891.51%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
โ‚ฌ6.98 B-3,472.17%๐Ÿ‡ซ๐Ÿ‡ท France
-โ‚ฌ0.25 Billion 19.74%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel